menu
    • menu

    Company profile for Longeveron

    NEW Drugs in Dev: 6
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Longeveron is a life-sciences company developing biological solutions for aging and aging-associated diseases. We believe regenerative medicine, through cell-based therapy, is a promising new approach to treating these conditions. Participating in FDA-evaluated clinical trials, we are currently testing our cell-based therapy product for a diagnosable ailment called Aging Frailty, a growing condition impacting approximately 50 ...
    Longeveron is a life-sciences company developing biological solutions for aging and aging-associated diseases. We believe regenerative medicine, through cell-based therapy, is a promising new approach to treating these conditions. Participating in FDA-evaluated clinical trials, we are currently testing our cell-based therapy product for a diagnosable ailment called Aging Frailty, a growing condition impacting approximately 50 million Americans over the age of 60.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LongeveronUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1951 NW 7TH AVENUE SUITE 520 MIAMI, FL 33136
    Telephone
    Telephone
    305.909.0840
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.longeveron.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/longeveron-llc
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Longeveron Reveals 2025 Financials, Updates Business
    Longeveron Reveals 2025 Financials, Updates Business

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257647/0/en/Longeveron-Announces-2025-Full-Year-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Longeveron To Present 2025 Financial Results, Host Conference
    Longeveron To Present 2025 Financial Results, Host Conference

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254766/0/en/Longeveron-to-Report-2025-Full-Year-Financial-Results-and-Host-Conference-Call-on-March-17-2026.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    Longeveron Finalizes $30M Private Placement
    Longeveron Finalizes $30M Private Placement

    11 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/11/3254131/0/en/Longeveron-Announces-Closing-of-Private-Placement-of-up-to-30-Million.html

    GLOBENEWSWIRE
    11 Mar 2026
    Share Share
    Longeveron Announces Private Placement Of Up To $30 Million
    Longeveron Announces Private Placement Of Up To $30 Million

    10 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/10/3252938/0/en/Longeveron-Announces-Private-Placement-of-up-to-30-Million.html

    GLOBENEWSWIRE
    10 Mar 2026
    Share Share
    Longeveron Publishes Phase 2b Stem Cell Study in Cell Stem Cell
    Longeveron Publishes Phase 2b Stem Cell Study in Cell Stem Cell

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244802/0/en/Longeveron-Results-of-Phase-2b-Clinical-Trial-Demonstrating-Stem-Cell-Therapy-Improved-Condition-of-Patients-with-Age-Related-Frailty-Published-in-Cell-Stem-Cell.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share
    Longeveron Names Stephen H. Willard as CEO
    Longeveron Names Stephen H. Willard as CEO

    13 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/13/3238336/0/en/Longeveron-Appoints-Stephen-H-Willard-as-Chief-Executive-Officer.html

    GLOBENEWSWIRE
    13 Feb 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search